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Abstract
Background: Drugs to protect the liver are frequently prescribed in some countries as part of
treatment for tuberculosis. The biological rationale is not clear, they are expensive and may do
harm. We conducted a systematic review to a) describe the ingredients of "liver protection drugs";
and b) compare the evidence base for the policy against international standards.
Methods: We searched international medical databases (MEDLINE, EMBASE, LILACS, CINAHL,
Cochrane Central Register of Controlled Trials, and the specialised register of the Cochrane
Infectious Diseases Group) and Chinese language databases (CNKI, VIP and WanFang) to April
2007. Our inclusion criteria were research papers that reported evaluating any liver protection
drug or drugs for preventing liver damage in people taking anti-tuberculosis treatment. Two
authors independently categorised and extracted data, and appraised the stated methods of
evaluating their effectiveness.
Results: Eighty five research articles met our inclusion criteria, carried out in China (77), India (2),
Russia (4), Ukraine (2). These articles evaluated 30 distinct types of liver protection compounds
categorised as herbal preparations, manufactured herbal products, combinations of vitamins and
other non-herbal substances and manufactured pharmaceutical preparations. Critical appraisal of
these articles showed that all were small, poorly conducted studies, measuring intermediate
outcomes. Four trials that were described as randomised controlled trials were small, had short
follow up, and did not meet international standards.
Conclusion: There is no reliable evidence to support prescription of drugs or herbs to prevent
liver damage in people on tuberculosis treatment.
Background
China has a long history of traditional medicine, based on
the theory of yin yang and its balance with qi (vital
energy) [1]. There are over 100,000 defined traditional
Chinese medicine therapies and 80% of these are herbal
combinations [2]. To treat tuberculosis (TB), traditional
Chinese medicine practitioners typically advocate a com-
bination of biomedical treatment to eliminate bacteria,
and traditional medicine to strengthen qi [1], and herbs to
protect the liver.
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and pyrizinamide have hepatotoxic effects. A meta-analy-
sis of studies involving several anti-tuberculosis drug reg-
imens estimates the incidence of liver toxicity is 2.6% with
co-administered isoniazid and rifampicin, 1.6% with iso-
niazid alone, and 1.1% with rifampicin alone [3]; some
estimates give the incidence of liver damage among peo-
ple taking anti-tuberculosis drugs in China to be much
higher – at around 15–30% of all patients [4,5].
The number of people being prescribing 'liver protection
drugs' worldwide is not known, but it is generally agreed
that it is almost universal for TB patients in China [6].
These drugs are either given to all patients on anti-tuber-
culosis treatment, or those with some liver function test
abnormalities. There is some emerging evidence that the
out of pocket costs to patients are high. For example, a
recent descriptive study of TB treatment and policy in one
municipality found that on top of the TB drugs (which are
free) patients were charged expensive fees for liver protec-
tion drugs', and this was an important reason why
patients interrupted drug taking [6]. Others report the
administration of additional non-TB drugs in China, at a
higher than necessary cost to patients [7].
There is no obvious biological rationale for these herbal
drugs. Yet clinicians and TB specialists in China appear
convinced that these various pharmaceutical and herbal
preparations may have a protective effects on the liver in
people taking anti-TB treatment. However, a primary con-
cern is patient adverse reactions to herbal drugs; some
Chinese herbs are known to cause acute hepatitis, and
other herbs used in phytomedicine can cause liver toxicity
and even liver failure [2]. It is unclear how the effects, and
safety, of these drugs are being evaluated in TB patients.
To help open up the debate in this area, we systematically
summarised what these agents are as reported in scientific
papers that describe evaluations of these liver protection
drugs; and critically appraised the evidence base against
international standards for appropriate scientific study
designs that could justify their use.
Methods
Search
We searched international medical databases (MEDLINE,
EMBASE, LILACS, CINAHL, Cochrane Central Register of
Controlled Trials, and the specialised register of the
Cochrane Infectious Diseases Group) and Chinese lan-
guage databases (CNKI, VIP and WanFang) to April 2007.
In the two step process, we firstly used combinations of
key words including: tuberculosis, liver damage, hepato-
protector, liver protection drug. From the literature iden-
tified we generated a list of compounds used. In the
second step, we searched the databases on the specific
names.
Inclusion criteria and application
We included research papers that reported evaluating any
liver protection drug or drugs for preventing liver damage
in people taking anti-tuberculosis treatment.
Data extraction
Two authors (HS, QL) screened titles and abstracts of
papers retrieved from English databases; BH and QL
screened titles and abstracts of articles retrieved from Chi-
nese databases. For studies written in Chinese, two
researchers independently categorised and extracted data
from the full text articles. An additional six studies from
Russia were included based on the English abstracts; sub-
sequent categorisation and extraction of information on
study design was done by a researcher based in Russia
who is also fluent in English.
Analysis
We categorised drugs and herbs using a modified version
of WHO standard definitions for the evaluation and
research of herbal medicines [8]. Herbal preparations
include comminuted or powdered herbal materials,
extracts of herbal materials, or preparations made by
steeping or heating herbal materials in beverages; finished
manufactured herbal products are made from one or
more herbs, may contain excipients (non-active sub-
stances combined with drugs to make them suitable for
administration), but do not include products with chem-
ically defined active ingredients; we defined non-herbal
preparations as either combinations of vitamins and other
non-herbal substances or pharmaceutical preparations
(manufactured drugs).
Effects
To detect any real effects over and above placebo, and
therefore determine the potential value of liver protection
drugs would require rigorous scientific testing using a ran-
domised, blinded, controlled trial. We examined the
design of each included study against international stand-
ards for clinical trials. We looked specifically at whether
the studies were prospective, whether patients were allo-
cated randomly to treatment groups, if studies were pla-
cebo-controlled, and whether authors defined the length
of follow up, or methods used to monitor adverse events.
Results
We identified 191 research papers (175 from the Chinese
databases; 16 from international databases) examining
liver protection drugs in TB patients. Overall, 85 research
articles reported evaluations of drugs or herbs to prevent
drug-induced liver damage in patients taking anti-tuber-
culosis treatment (we excluded 106 studies of drugs usedPage 2 of 8
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(77); other countries were India (2); Russia (4); Ukraine
(2).
a) What are the ingredients?
We categorised the ingredients of drugs and herbs accord-
ing to the WHO classification of traditional herbal medi-
cines [8]; we added categories to describe drugs derived
from non-herbal and other substances (see table 1).
Three studies examined herbal preparations for prevent-
ing liver damage in TB patients. In two studies from
China, the preparations contained 11 different herbs; in
one study different combinations of herbs were adminis-
tered to participants depending on their vital energy (qi)
and bodily balance (yin yang). One study from Russia
reported the effect of herbal infusions containing on aver-
age 25 different herbs tailored to individual patient needs.
51 studies evaluated manufactured herbal products.
Extract of milk thistle (Silymarin) was the most frequently
evaluated in the studies we identified (9 studies from
China). Oleanic acid (extract of Swertia) and glycyrrhizin
(extract of Liquorice) were also common in studies con-
ducted in China. Two studies in India evaluated combina-
tions of many different indigenous herbs and plants; one
trial examined Stimuliv tablets, the other a capsule called
Optiliv.
We found 27 reports of the hepatoprotective effect of
combinations of vitamins and other non-herbal sub-
stances in TB patients. The most commonly evaluated was
Tiopronin, a ramification of glycine (17 studies in China);
three studies used the drug named 'liu pu luo ning', the
other 14 were of the drug 'kai xi lai'. The injectable anti-
oxidant glutathione (GSH) was also commonly used in
studies conducted in China; two different trade names of
this drug were evaluated, 'tai te' and 'a tuo mo lan'.
Four studies reported on the effect of manufactured phar-
maceutical preparations. Three studies conducted in
China concerned Glucurolactone. One study from Russia
concerned the drug Zixoryn.
b) What is the evidence base for their use?
Table 2 summarises the design features of studies evaluat-
ing liver protection drugs grouped into those conducted
in China, and those carried out in other countries (India,
Russia and Ukraine). From the Chinese studies, we iden-
tified 51 prospective studies, where TB patients were fol-
lowed forward in time and prior to the occurrence of liver
damage. In most of these studies exact recruitment and
follow up times were not clearly stated. All eight studies
conducted in other countries were classified as prospec-
tive, but again recruitment and follow up times were not
clearly stated.
No studies conducted in China were placebo controlled;
most compared one liver protection drug with another or
anti-tuberculosis treatment alone. Most studies conducted
in other countries were open trials, comparing one drug to
another with no placebo.
It is interesting to note that no studies in China described
the methods for monitoring for adverse events, and more
than half did not report adverse events at all. Six out of
eight non-Chinese papers provided methods for monitor-
ing adverse events.
The length of follow up reported in the Chinese studies
varied from less than a month, to more than six months;
in 22 studies the exact length of follow up was unclear.
The main outcomes assessed in the included studies were
indicators of drug-induced liver damage measured by liver
function test, such as ALT and AST.
Reported as randomised
Overall we identified five studies that reported to be ran-
domised. Three studies conducted in China mentioned
randomly allocating patients to treatment groups using
random number tables. Two studies conducted in India
mentioned randomisation, but only one stated using ran-
dom number tables to allocate patients. Methods to con-
ceal allocation were not described in the studies from
China; one of the Indian studies described concealing the
drug codes in a sealed envelope. Two of the studies con-
ducted in China followed patients for two months or less;
the other did not specify a follow-up period. The study in
India that was clearly randomised followed patients for
less than 2 months (45 days), and the study where ran-
domisation was unclear followed patients for two
months. All three Chinese studies included less than 250
participants (one included only 80); both the Indian stud-
ies included less than 150 participants.
Discussion
This is the first attempt that we are aware of to systemati-
cally summarise the ingredients of drugs and herbs used
to protect the liver in patients taking anti-tuberculosis
treatment, and to scrutinise the methods used to evaluate
their effects. The literature suggests a large difference in
the proportion of patients with hepatotoxicity in China
(15–30%) compared to elsewhere (about 2.6%). We
believe this is due to varying definitions and understand-
ing of what hepatoxicity is, with a more liberal interpreta-
tion in the Chinese context. However, we have not
systematically examined the literature to clarify this.Page 3 of 8
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Table 1: Categorisation of drugs and herbs by main ingredients
Type Name Description of ingredients Number of 
studies
Country
Herbal preparations Yue hua wan Various combinations of more than 11 
Chinese herbs decocted in water
1 China [10]
Bu pi yang fei bao gan decoction 11 herbs decocted in water 1 China [12]
Phytotherapy Infusions of a combination of herbs (on 
average 25) tailored to individual patients
1 Russia [13]
Finished manufactured herbal 
products
Hu gan pian Tablet including a combination of six 
ingredients 
(herbs, animal extract, green bean)
8 China [14-21]
Silymarin Extract of milk thistle 11 China [22-32]
Astragalus Plant extract given intravenously 1 China [33]
Astragalus dasyanthus Tincture containing: coumarins; 
ferrocoumarins; tanning substances; sugars; 
saponins; ascorbic acid; flavonoids; 
phytosterols; tocopherols
1 Russia [34]
Biphenyldicarboxylate Tablet with extract of wu wei zi plant 2 China [35,36]
Biphenyldicarboxylate Extract of wu wei zi combined with 
glucurolactone
1 China [37]
Wu zhi capsule Capsules with extract of the fruit of the wu 
wei zi plant
3 China [38-40]
San shen bao gan capsule Capsules containing combination of 13 herbs 1 China [41]
Hugan yi fei granule Granule containing a combination of 12 
herbs
1 China [42]
Oleanolic acid Tablet with extract of Swertia herb 5 China [43-47]
Hugan yao Exact of Swertia herb combined with inosine 
and Vit C
1 China [48]
Dan shen Injectable preparation of Chinese sage 
(Salvia Miltiorrhiza Bunge)
3 China [49-51]
Stimuliv Tablets containing a combination of: 
Andrographis Paniculata; Eclipta alba; 
Peumas Boldus Molina; Cynara scolymus; 
Fumaria perviflora
1 India [52]
Galstena Chelidonium majus; Taraxacum officinale; 
Carduus crispus 
(curled thistle extracted with enthanol)
1 Russia [53]
Optiliv Capsules containing extracts of: 
Andrographis paniculata; Picrorhiza kurroa; 
Eclipta alba; Boerhaavia diffusia; Azadirachta 
indica; Swetia chirata; Solanum nigrum; 
Terminalia arjuna; Aphanamixis rohituka; 
Terminalia chebula; Furmaria indica; 
Excipients
1 India [11]
Glycyrrhizin Capsules or injection containing extract of 
liquorice (gan cao)
6 China [54-59]
Anisodamine Tablet containing plant extract 1 China [60]
Spirin or Spirulina Derived from blue-green algae, contains 
proteins, vitamins and essential amino acids
2 China [61,62]
1 Ukraine [63]
Combinations of vitamins and 
other non-herbal substances
Tiopronin 
(liu pu luo ning or kai xi lai)
Ramification of Glycine (amino acid) 17 China [64-80]
Glutathione 
(GSH) (tai te or a tuo mo lan)
Injectable antioxidant 5 China [81-85]
ATP Adenosine Triphosphate 1 China [86]
Inosine Inosine combined with vitamin C 1 China [87]
Essentiale Vitamin B6, vitamin B12, derivatives of 
vitamin B3 (nicotinamide), vitamin E and 
essential phospholipids
1 China [88]
Gan ning pian Liver hydrolysate, compounds of vitamin B, 
inositol, vitamin B6 and vitamin B12
1 China [89]
Tocopherol acetate Vitamin E 1 Ukraine [90]
Pharmaceutical preparations Glucurolactone Manufactured drug 3 China [91-93]
Zixoryn Manufactured drug 1 Russia [94]
BMC Public Health 2008, 8:365 http://www.biomedcentral.com/1471-2458/8/365Our study revealed thirty distinct types of liver protection
drugs or preparations used in patients with TB, and each
contains a complex combination of herbal extracts, vita-
mins or compounds. Few studies provided a clear biolog-
ical or clinical rationale for the use of specific herbs or
drugs, but we know that some of the herbs identified in
our summary have already been studied in China with
researchers claiming general hepatoprotective properties,
although not in TB patients. For example, Silymarin is
known to be widely used as a remedy for liver diseases and
glycyrrhizin has been used in chronic viral hepatitis [2,9].
The numerous ingredients of Chinese herbs and drugs
make it more difficult to determine the active ingredients
or properties of these preparations or drugs, something we
recognised when extracting information from our
included studies. It seems unconvincing that so many dif-
ferent preparations all have properties that protect against
liver damage by drugs used to treat TB, and we do not
know of any convincing biological mechanism. In addi-
tion, we do not know the number of studies that were
sponsored by pharmaceutical companies as this is not
generally reported in Chinese research papers.
Relatively few studies we identified evaluated herbal prep-
arations; most were concerned with the effect of finished
manufactured herbal products. Herbal preparations are
more complicated to evaluate, and it has been suggested
that a conventional randomised controlled and blinded
trial design might not be appropriate [8]. Preparations
usually have a distinct smell or taste and the herbs used
are sometimes blended to suit individual patient needs;
all of which preclude blinding of participants and trialists,
and use of placebo preparations. For example, one study
of the Chinese herbal preparation 'yue hua wan' claimed
to be a prospective study that used a random number
table to allocate patients to standard anti-tuberculosis
treatment plus the herbal preparation or anti-tuberculosis
treatment alone [10]. The study is weakened by the lack of
a placebo control, but the published report does not
describe the preparation in detail, so we cannot determine
whether a placebo preparation would have been possible.
Studies that fail to use a placebo-control cannot deter-
mine the effect of the herb or drug relative to a control
treatment and this is less useful for clinical decision mak-
ing.
Our summary indicates that the evidence base for the use
of liver protection drugs in TB patients comprises mainly
small, poorly conducted studies that do not reach the
standards of trials used in reliable systematic reviews such
as those produced by the Cochrane collaboration. Only
one study, out of 85 we identified in the international lit-
erature, appeared to be a prospective, randomised, pla-
cebo controlled trial of a manufactured herbal product
[11]. But the trial followed patients for 45 days only, too
short a time period to identify liver damage or toxicity; the
authors failed to specify particular outcomes a priori; and
the study included only 70 patients.
Sample size is a critical consideration in relation to the
primary outcome in studies evaluating liver protection
drugs-liver damage or toxicity. We have estimated that to
Table 2: Key design features of studies evaluating liver protection drugs
Study characteristics Studies conducted in China (n = 77) Studies conducted in other countries (n = 8)
Length of follow up
<1 month 5 1
<6 months 19 4
> or = 6 months 31 3
Unclear 22 0
Clearly prospective
Prospective 51 8
Retrospective 18 0
Unclear 8 0
Random allocation
Clear 3 1
No 20 6
Quasi 15 0
Unclear 39 1
Comparisons
Placebo 0 2
Anti-TB drugs alone 32 2
Alternative liver protection drug(s) 42 4
No 3
Methods for monitoring adverse events stated 0 6
Adverse events reported 29 2Page 5 of 8
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30% in China [4,5] would require a sample size of 1145
for each trial arm with 95% confidence and 90% power,
and if the calculation is based on a global incidence of 1–
2% [3], a much larger sample size would be required. It
would be impractical and expensive to run trials of this
size, and trials of these drugs are not really justified.
Although we classified most of the studies we identified
from the Chinese literature as 'prospective', only three
appeared to randomly allocate participants to groups, and
these were not placebo controlled. Eighteen studies
appeared to be retrospective, and used patient records to
examine outcomes historically. Generally we found it dif-
ficult to determine from the short full text journal reports
which particular observational design the authors had fol-
lowed. Most studies classified as retrospective appeared to
be case reports or case series. The reports generally did not
describe the research procedures in detail, and it was diffi-
cult to determine which studies were case-controlled.
An important finding is the lack of attention in the
research papers to adverse events associated with the
drugs or herbs used. Some studies mentioned adverse
events, but did not describe methods used routinely to
monitor patients for events; a large number of the Chinese
studies did not mention adverse events at all. Given the
existing concerns over the safety of some herbs in use [2],
it is important that studies include methods to routinely
assess participants for adverse events; that samples are
large enough; and studies follow patients over a sufficient
period of time to detect infrequent events.
Other authors report poor methodological quality of
studies evaluating herbal preparations; often studies do
not adequately randomise participants, do not specify
outcome measures or end points, contain small sample
sizes, and suffer from publication bias [2]. WHO provide
guidelines for good practice in conducting clinical trials of
herbal medicine, and recommend the design of trials be
adapted to the peculiarities of herbal medicines [8].
Conclusion
In terms of policy implications, this review indicates there
is no reliable evidence to support taking liver protection
drugs with TB treatment. Indeed some may do harm. Thus
there is no medical reason to continue prescribing them;
and, given the wide variety of compounds, many of which
may have side-effects, it is more likely that they will do
more harm than good. Understanding of what liver toxic-
ity is and criteria for diagnosis are probably also different
which further complicates any comparison.
In terms of research, it could be argued that trials follow-
ing accepted international standards for conduct and
reporting are required. However, given the poor rationale
for using the drugs and large sample size required, then
the reasons for doing a proper RCT will be limited. The
one justification could relate to the fact that they are
widely prescribed, so identifying no effect, or a harmful
effect, could potentially be a powerful influence on cur-
rent policies.
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